Caixin App
Newsletter
Weekly Magazine
Go
Sections
Sections
Finance
Business
Tech
Economy
China
World
Commentary & Analysis
Weekend Long Read
Video
ESG
Topics
China Goes Global
Asia New Vision Forum 2025
Asia New Vision Forum 2024
Selected
CX Daily
Weekly Must-Read
Caixin Briefs
Economic Indexes
Caixin Explains
News Graphics
ThinkChina
The Wall Street Journal
Podcast
Highlights
Newsletter
Events
Impact
Asia Central Banking
Promotion
中文
SUBSCRIBE
Clear
GO
Sort by:
Newest
Newest
Relevance
Oldest
Type:
All
All
News
CX Tech
Videos
Podcast
Gallery
In-Depth
Time:
Any Time
Any time
Past 24 Hours
Past Week
Past Month
Past Year
Custom Range
Range:
All
All
Headline
Byline
Full Text
Reset
Showing search results for
cui xiaotian
In Depth: China’s Tech Giants Burn Cash to Try to Dominate AI Health Care
AstraZeneca Doubles Down on China With 100 Billion Yuan Pledge
AstraZeneca Doubles Down on China With 100 Billion Yuan Pledge
Analysis: New Safety Rules Unlikely to Trigger Mass Delistings of Chinese Traditional Medicines
AbbVie Bets Big on Chinese Cancer Drug in $5.6 Billion Licensing Deal
In Depth: The Battle to Make Cancer’s ‘Living Drug’ Affordable
Cover Story: Chinese Medicine Injections Face Rigorous Regulation for the First Time
Ant Group Elevates Health Care to Core Business in Major AI Push
Pharma Giants Scale Back in China Amid Price Wars and Regulatory Pressure
Cancer Screening Star New Horizon Health to Delist in Hong Kong Amid Fraud Claims
Load more
Sign In
Sign In
Cancel
Remember me
Forgot Password
OR
Sign in with Google
Sign in with Facebook
Sign in with 财新通